Single Cell Genomics Markets: Forecasts by End User & Technology with Executive and Consultant Guides Including Customized Forecasting and Analysis 2021 to 2025
March 2021 edition
"Single Cell Genomics (SCG) identifying new forms of life, driving enormous new research area with wide healthcare application"
Single cell genomics (SCG) is emerging as a mainstay of scientific research and development. Just coming out of the lab it is finding its footing in new clinical applications especially related to immuno-oncology and microbiology. But the largest market is still in research and the market is booming as understanding the genomics of individual cells opens up a whole new world of biotechnology.
This is a complex area however this readable report will bring the entire management team up to speed, on both the technology and the opportunity.
The technology is moving faster than the market; find the opportunities and the pitfalls whilst understanding growth expectations and the ultimate potential market size.
All report data is available in Excel format on request with the corporate license.
Subscribe and Save
By signing up for the annual subscription, updates to this report will be automatically provided free of charge for a period of one year from initial purchase. These updates can include revised forecasts as markets increase or contract and exclusive market commentary not seen anywhere else. With the effects of COVID-19 being felt across all markets it has never been more crucial to stay fully informed with real-world actionable data. Subscribe to this report and receive ongoing market forecasting and analysis for sharpened strategic planning throughout the year.
- Quarterly report updates
- Summary of significant developments and market changes
- Phone consultation and assistance on request for the duration of the subscription
Our research makes you the expert in your organization. Get our research team working for you by ordering this comprehensive report. Check all your licensing options, however your order is available as a credit if you wish to upgrade. We wrote this report and are ready by phone or email to help you use it.
Assistance and additional breakout data relevant to your own area(s) of interest is available free of charge with the corporate license.
ABOUT THE LEAD AUTHOR
Mr. Greg Powell, B.SC., M.B.A is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell’s education includes:
- B.Sc. (Chemistry) University of BC
- M.B.A. (Finance and Policy) University of BC
- Market Research Seminar - Burke Institute
- Finance for Senior Executives - Harvard Business School